Kisspeptin

A hypothalamic peptide studied in reproductive-endocrinology and HPG-axis research.

Kisspeptin is catalogued here as a reference compound for neuropeptide and cognitive research. The entry covers its chemical identity and the public databases that describe it; it is not a usage guide.

Kisspeptin appears in the neuropeptide and cognitive literature, primarily in in-vitro and preclinical (animal) models. This page indexes 3 verified primary papers on Kisspeptin (1 rodent, 1 other and 1 in-vitro), each resolvable by PMID or DOI. Peptidoteca summarizes the proposed mechanism class and the primary sources rather than human outcomes; for the wider library, see the research library.

Attributed, study-level findings from the verified literature indexed on this page — preclinical observations, not clinical outcomes:

• Wei Suocheng et al. (2026), Molecular Reproduction and Development [rodent] — In a mouse study including cultured ovarian granulosa cells, Kisspeptin-10 was associated with increased granulosa-cell proliferation, ovarian follicle development, and higher serum progesterone and estradiol, reportedly acting through the PI3K/AKT/ERK signaling pathway.
• Szysiak N et al. (2026), Journal of Veterinary Research [other] — In ewe lambs tracked across the peripubertal period, plasma kisspeptin-10 and neurokinin B concentrations rose with age while dynorphin A declined; the onset of ovarian activity coincided with concurrent increases in kisspeptin-10 and neurokinin B alongside reduced dynorphin A.
• Szysiak N et al. (2025), Journal of Veterinary Research [in-vitro] — In an in-vitro study of cultured anterior pituitary cells from pubescent ewes, neurokinin B was reported to increase kisspeptin-10 secretion in a dose- and time-dependent manner, whereas dynorphin A had no significant effect on its release.

No. Kisspeptin is supplied for laboratory (in-vitro) research use only. It is not approved by the FDA or any comparable regulator for human or veterinary use, and nothing on this page constitutes medical advice, dosing guidance or a treatment recommendation.

Most available evidence for Kisspeptin is preclinical — in-vitro and animal models — and findings in those models do not establish efficacy or safety in humans. Human clinical data is limited or absent, and Kisspeptin is not an approved drug. Treat the literature as mechanistic research, not clinical guidance.